Aytu submits Cotempla XR-ODT site transfer PAS to FDA; expects 15% margin improvement on ADHD brands

AYTU BIOPHARMA, INC

Submitted Cotempla XR-ODT Prior Approval Supplement to FDA; expects six-month review with approval by late 2023/early 2024.
Adzenys XR-ODT site transfer PAS already approved; production shifting to contract manufacturer.
Upon completion of both site transfers, expects ~15% margin improvement for ADHD product line.
CEO states outsourced manufacturing of Adzenys and Cotempla expected to begin by late 2023/early 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.